ACTINEER

Chemical substances, chemical materials and chemical preparations for use in the manufacture of medical and/or radiopharmaceutical products; chemical raw materials, in particular actinium-225 radiochemical and/or bismuth-213, for the formulation of radiopharmaceutical products.

Radiopharmaceutical diagnostic and/or therapeutic preparations for medical and/or pharmaceutical purposes, in particular radiopharmaceutical preparations for endoradionuclide therapy, brachytherapy, positron emission tomography (PET), single photon emission computed tomography (SPECT), target radionuclide therapy and peptide receptor radionuclide therapy (PRRT); radiopharmaceutical products, in particular actinium-containing and/or bismuth-containing radiopharmaceutical products in GMP [Good Manufacturing Practice] quality; radiopharmaceutical preparations for use in oncology, in particular radiopharmaceuticals containing radioisotopes, in particular actinium-225 and/or bismuth-213; radiopharmaceuticals containing medical radioisotopes with longer half-lives, in particular actinium-225 and/or bismuth-213 for the treatment of tumour diseases; target radiopharmaceuticals containing a target molecule, in particular a peptide or an antibody, depending on the indication, and a medical radioactive isotope; radiopharmaceuticals containing actinium-225 and/or bismuth-213 and its complexes.

Medical instruments, apparatus and containers for the production of radiopharmaceutical preparations, in particular for the production of actinium-225 and/or bismuth-213 in GMP quality; control, regulation and measuring apparatus as parts of medical instruments, apparatus and containers included in this class, in particular apparatus for the production of a radiotherapeutic or radiodiagnostic substance, in particular for the production of actinium-225 and/or bismuth-213 in GMP quality; radionuclide generator for radiopharmaceutical purpose.

Scientific and technological services and research relating to the use of actinium-225 and/or bismuth-213 or other alpha emitters, in particular medical and pharmacological research services relating to the use of actinium-225 and/or bismuth-213 or other alpha emitters.

Medical services, in particular services relating to radiotherapeutic and radiodiagnostic oncology, cardiology, angiology, neuroradiology, nuclear medicine and brachytherapies including intercavitary, interstitial and intravascular brachytherapy, radionuclide labelling, PET and SPECT scanning and radionuclide therapy, peptide receptor radionuclide therapy (PRRT), personal nuclear medicine and precision oncology; medical services for theranostics in the field of precision oncology.